Alemtuzumab in Sézary syndrome: efficient but not innocent.
Mycosis fungoides is the most common form of cutaneous T-cell lymphomas. The related Sézary syndrome is a more aggressive form in which the skin is diffusely affected and the peripheral blood is involved. Although easily managed during its early phases, late-stage mycosis fungoides/Sézary syndrome is usually difficult to treat and becomes refractory to chemotherapy. Recently, promising case-based results have been obtained with alemtuzumab, a humanized immunoglobulin G1 monoclonal antibody that binds to CD52 cell surface antigens, in the treatment of advanced stage mycosis fungoides/Sézary syndrome. We report a case of Sézary syndrome treated successfully with alemtuzumab but who died of treatment-related infection.
Ure
Umit Barbaros
UB
Istanbul University Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Hematology, Istanbul University Cerrahpasa Medical Faculty, 34300, Istanbul, Turkey.
Ar
Muhlis Cem
MC
Salihoglu
Ayse
A
Guner
Sebnem Izmir
SI
Baran
Ahmet
A
Oguz
Oya
O
Ferhanoglu
Burhan
B
D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000009:adverse effects* / Q000627:therapeutic use; D015703:Antigens, CD; D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000074301:CD52 Antigen; D003587:Cytomegalovirus / Q000235:genetics / Q000302:isolation & purification; D003586:Cytomegalovirus Infections / Q000139:chemically induced*; D004279:DNA, Viral / Q000032:analysis; D017809:Fatal Outcome; D006023:Glycoproteins / Q000037:antagonists & inhibitors; D006801:Humans; D008231:Lymphopenia / Q000139:chemically induced*; D008297:Male; D008875:Middle Aged; D009894:Opportunistic Infections / Q000139:chemically induced*; D012751:Sezary Syndrome / Q000188:drug therapy* / Q000473:pathology; D012867:Skin / Q000473:pathology
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D015703:Antigens, CD; D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents; D000074301:CD52 Antigen; C000613862:CD52 protein, human; D004279:DNA, Viral; D006023:Glycoproteins; D000074323:Alemtuzumab